RCS - Cizzle Biotechnology - Launch of New Website

Cizzle Biotechnology HoldingsAnnouncement

14/04/2025 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250414:nRSN8834Ea&default-theme=true

RNS Number : 8834E  Cizzle Biotechnology Holdings PLC  14 April 2025

REACH

14 April 2025

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Launch of New Website

Cizzle Biotechnology, the UK based diagnostics developer of early cancer
tests, is pleased to announce that it has launched its new corporate website,
which can be viewed at:

https://cizzlebiotechnology.com (https://cizzlebiotechnology.com)

 

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

 

"I am delighted to announce that our new website is now live for all
stakeholders including shareholders, investors and customers, to access a wide
range of information and latest news on the Company's status and products.
This is an exciting time for Cizzle Biotechnology as we continue to finalise
our near term regulatory and launch plans in the USA as part of our global
strategy to bring the non-invasive, cost effective, CIZ1B Biomarker test for
early-stage lung cancer to market.  The new website is designed to provide a
user-friendly interface for all stakeholders and we look forward to adding new
content as part of an enhanced communication strategy to support the Company's
growth."

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                                     +44(0) 20 3328 5656
 John Depasquale/Piers Shimwell (Corporate Finance)
 Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited            +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a
naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B
biomarker is highly associated with the presence of early-stage cancer. The
Company has developed CIZ1B into a non-invasive, cost-effective blood test to
help in the early detection of lung cancer and has now entered into commercial
royalty-bearing arrangements to license its proprietary technology, and into
collaborations with centres of excellence in cancer care.  Cizzle was
admitted to trading on the Main Market of the London Stock Exchange in May
2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUSVWRVOUSARR